Funding for this research was provided by:
Psioxus Therapeutics Limited (N/A)
Received: 31 July 2018
Accepted: 13 January 2019
First Online: 28 January 2019
Ethics approval and consent to participate
: The study was approved by the institutional review board of each participating center and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation of Good Clinical Practice guidelines. All patients provided written informed consent before study entry.
: Not applicable.
: J-PM, RS, SR, ID, LD, and KG have no potential conflicts of interest to declare.CW-B and GP were employees of PsiOxus Therapeutics Limited at the time of the study.SA, BC, KF, and HM-J are employees of PsiOxus Therapeutics Limited.JB is an employee, company director, and shareholder of PsiOxus Therapeutics Limited.EC is a paid employee of START Madrid and HM Hospitales Group and is president and founder of Foundation INTHEOS. EC has stock and/or ownership interests in START Madrid, OncoArt Associated and International Cancer Consultants and has received honoraria from HM Hospitales Group and travel/accommodation expenses from Roche/Genentech. EC has received research-related funding from AstraZeneca, Novartis, BeiGene and START Madrid. EC has received consulting and/or advisory fees from Abbvie, Amcure, AstraZeneca, Celgene, EUSA Pharma, GLG, Guidepoint Global, Janssen-Cilag, Nanobiotix, Novartis, Pfizer, PsiOxus Therapeutics Limited, Roche/Genentech, Seattle Genetics, SERVIER, and START Madrid.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.